Please wait while the formulary information is being retrieved.
ETOPOSIDE (ETOPOSIDE)
- Refractory malignant tumor of testis
- Small cell lung carcinoma
20 mg/mL intravenous solution
- Dosage information is not available
20 mg/mL intravenous solution
- Dosage information is not available
20 mg/mL intravenous solution
- Dosage information is not available
20 mg/mL intravenous solution
- Dosage information is not available
Diffuse large b-cell lymphoma
- Infuse 50 mg/m2 by intravenous route once
- Infuse 120 mg/m2 by intravenous route once
- Infuse 100 mg/m2 by intravenous route once daily
- Infuse 100 mg/m2 by intravenous route once daily for 3 days
- Infuse 80 mg/m2 by intravenous route once daily
- Infuse 80 mg/m2 by intravenous route once daily for 3 days
- Infuse 75 mg/m2 by intravenous route once daily
- Infuse 75 mg/m2 by intravenous route once daily for 4 days
- Infuse 40 mg/m2 by intravenous route once daily
- Infuse 40 mg/m2 by intravenous route once daily for 4 days
- Infuse 50 mg/m2 by continuous infusion route once daily for 4 days
Progressive diffuse large b-cell lymphoma
- Infuse 50 mg/m2 by intravenous route once
- Infuse 120 mg/m2 by intravenous route once
- Infuse 100 mg/m2 by intravenous route once daily
- Infuse 100 mg/m2 by intravenous route once daily for 3 days
- Infuse 80 mg/m2 by intravenous route once daily
- Infuse 80 mg/m2 by intravenous route once daily for 3 days
- Infuse 75 mg/m2 by intravenous route once daily
- Infuse 75 mg/m2 by intravenous route once daily for 4 days
- Infuse 40 mg/m2 by intravenous route once daily
- Infuse 40 mg/m2 by intravenous route once daily for 4 days
- Infuse 50 mg/m2 by continuous infusion route once daily for 4 days
Refractory malignant tumor of testis
- Infuse 50 mg/m2 over 5-210 minute(s) by intravenous route once daily on days 1 through 5 of each treatment cycle
- Infuse 100 mg/m2 over 5-210 minute(s) by intravenous route once dailyon days 1 through 5 of each treatment cycle
- Infuse 100 mg/m2 over 5-210 minute(s) by intravenous route once dailyon days 1, 3, and 5 of each treatment cycle
Small cell lung carcinoma
- Infuse 35 mg/m2 over 5-210 minute(s) by intravenous route once daily for 4 consecutive days
- Infuse 50 mg/m2 over 5-210 minute(s) by intravenous route once daily for 5 consecutive days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- ketoconazole
- Versacloz
Severe
Moderate
- cyclosporine
- cyclosporine modified
- Gengraf
- Neoral
- Sandimmune
- Interstitial pneumonitis
- Lactating mother
- Pulmonary fibrosis
- Severe infection
- Severe neutropenic disorder
- Severe thrombocytopenia
Contraindicated
- Anemia
- Bone marrow depression
- Drug-induced hepatitis
- Hemorrhage
- Leukopenia
- Metabolic acidosis
- Neutropenic disorder
- Pregnancy
- Renal disease with moderate to severe impairment
- Thrombocytopenic disorder
Severe
Moderate
- Hypoalbuminemia
ETOPOSIDE (ETOPOSIDE)
- Refractory malignant tumor of testis
- Small cell lung carcinoma
- Anemia
- Leukopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- Alopecia
- Anorexia
- Chills
- Constipation
- Fever
- Nausea
- Stomatitis
- Vomiting
More Frequent
Severe
Less Severe
- Extravasation injury
- Acute abdominal pain
- Diarrhea
- Dizziness
- Dysgeusia
- General weakness
- Peripheral neuropathy
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute renal failure
- Allergic dermatitis
- Anaphylaxis
- Drug-induced hepatitis
- Dyspnea
- Interstitial pneumonitis
- Laryngismus
- Maculopapular rash
- Optic neuritis
- Pruritus of skin
- Pulmonary fibrosis
- Radiation recall syndrome
- Secondary acute myeloid leukemia
- Skin rash
- Stevens-johnson syndrome
- Tachycardia
- Toxic epidermal necrolysis
- Urticaria
- Wheezing
Less Severe
- Cortical blindness
- Dysphagia
- Hypersensitivity drug reaction
- Hypertension
- Hypotension
- Injection site sequelae
- Malaise
- Skin pigmentation enhancement
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Etoposide
Anaphylactic reactions reported with IV use. Safety and efficacy not established.
- 1 Day – 18 Years
- Anaphylactic reactions reported with IV use. Safety and efficacy not established.
Etoposide
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Etoposide
Potential severe adv effects including bone marrow depression,carcinogenicity
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Potential severe adv effects including bone marrow depression,carcinogenicity |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Etoposide
General-Increased risk of myelosuppression, asthenia, gastrointestinal effects, infection, and alopecia. Renal-Adjust dose in renal impairment.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may cause certain severe blood and bone marrow problems (low red blood cells/white blood cells/platelets). This can affect your body's ability to stop bleeding or fight infection. Tell your doctor right away if you develop unusual tiredness, signs of infection (such as fever, chills, persistent sore throat), or easy bruising/bleeding (such as black stools, bloody vomit).
| Refractory malignant tumor of testis | |
| C62 | Malignant neoplasm of testis |
| C62.0 | Malignant neoplasm of undescended testis |
| C62.00 | Malignant neoplasm of unspecified undescended testis |
| C62.01 | Malignant neoplasm of undescended right testis |
| C62.02 | Malignant neoplasm of undescended left testis |
| C62.1 | Malignant neoplasm of descended testis |
| C62.10 | Malignant neoplasm of unspecified descended testis |
| C62.11 | Malignant neoplasm of descended right testis |
| C62.12 | Malignant neoplasm of descended left testis |
| C62.9 | Malignant neoplasm of testis, unspecified whether descended or undescended |
| C62.90 | Malignant neoplasm of unspecified testis, unspecified whether descended or undescended |
| C62.91 | Malignant neoplasm of right testis, unspecified whether descended or undescended |
| C62.92 | Malignant neoplasm of left testis, unspecified whether descended or undescended |
| Small cell lung carcinoma | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| 0-9 | A-Z |
|---|---|
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| C62 | Malignant neoplasm of testis |
| C62.0 | Malignant neoplasm of undescended testis |
| C62.00 | Malignant neoplasm of unspecified undescended testis |
| C62.01 | Malignant neoplasm of undescended right testis |
| C62.02 | Malignant neoplasm of undescended left testis |
| C62.1 | Malignant neoplasm of descended testis |
| C62.10 | Malignant neoplasm of unspecified descended testis |
| C62.11 | Malignant neoplasm of descended right testis |
| C62.12 | Malignant neoplasm of descended left testis |
| C62.9 | Malignant neoplasm of testis, unspecified whether descended or undescended |
| C62.90 | Malignant neoplasm of unspecified testis, unspecified whether descended or undescended |
| C62.91 | Malignant neoplasm of right testis, unspecified whether descended or undescended |
| C62.92 | Malignant neoplasm of left testis, unspecified whether descended or undescended |
Formulary Reference Tool